Business Context and Reporting Period
This Form 8-K Current Report was filed by Pacific Biosciences of California, Inc. (PacBio) on June 24, 2022. The filing discloses the entry into a material definitive agreement with Invitae Corporation.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the terms of a contractual agreement rather than financial performance metrics.
Material Changes and Agreement Details
On June 24, 2022, PacBio entered into an Amended and Restated Development and Commercialization Agreement with Invitae Corporation, replacing the original agreement dated January 12, 2021. Key terms include:
- Development Role: PacBio will continue to receive feedback from Invitae regarding new sequencing systems, but this is not contractually required. PacBio retains full discretion over development plans.
- Cost Reimbursement: Invitae is not contractually obligated to reimburse PacBio for development costs under the new agreement.
- Consideration: In exchange for non-refundable development costs previously paid by Invitae, PacBio will provide credits and discounted pricing for current and in-development sequencing systems.
- Pricing Rights: Subject to conditions, Invitae is entitled to most favored pricing for Sequel IIe systems and certain in-development systems.
- Termination: Either party may terminate the agreement if the other remains in material breach after a cure period.
Outlook, Risks, and Contingencies
Management notes that there can be no assurances that in-development sequencing systems will continue to be developed, be successfully developed, or become available for commercial sale. The agreement is contingent on the successful progression of these development programs.
Investor Verification Checklist
- Verify the specific value of non-refundable development costs previously paid by Invitae that are being credited.
- Review the full Amended and Restated Agreement filed as an exhibit to the Form 10-Q for the quarter ended June 30, 2022.
- Assess the commercial viability and timeline of the "in-development sequencing systems" referenced in the pricing terms.
- Confirm the specific conditions required for Invitae to receive most favored pricing.